Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis.
- DOI
- 10.1136/egastro-2026-100598
- Published
- 2026
- Container
- eGastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/egastro-2026-100598,
title = {Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis.},
author = {Roblin X and Mechi F and Berger AE and Fumery M and Nancey S and Hébuterne X and Carbonnel F and Altwegg R and Barrau M and Sparrow MP and Duru G and Paul S},
year = {2026},
journal = {eGastroenterology},
doi = {10.1136/egastro-2026-100598},
url = {https://doi.org/10.1136/egastro-2026-100598}
}RIS
TY - JOUR TI - Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis. AU - Roblin X AU - Mechi F AU - Berger AE AU - Fumery M AU - Nancey S AU - Hébuterne X AU - Carbonnel F AU - Altwegg R AU - Barrau M AU - Sparrow MP AU - Duru G AU - Paul S PY - 2026 JO - eGastroenterology DO - 10.1136/egastro-2026-100598 UR - https://doi.org/10.1136/egastro-2026-100598 ER -
APA
X, R., F, M., AE, B., M, F., S, N., X, H., F, C., R, A., M, B., MP, S., G, D., & S, P. (2026). Early decline in anti-integrin αvβ6 autoantibodies strongly predicts 1-year clinical remission in vedolizumab-treated patients with ulcerative colitis.. eGastroenterology. https://doi.org/10.1136/egastro-2026-100598
Source records
- pubmed · retrieved 2026-11-10T13:46:07.877Z
- europe-pmc · retrieved 2026-11-10T13:46:07.876Z
- doaj · retrieved 2026-11-10T13:46:07.876Z